T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$1.66B |
| 2 |
KLA
KLAC
|
+$1.39B |
| 3 |
T-Mobile US
TMUS
|
+$1.38B |
| 4 |
Eli Lilly
LLY
|
+$1.37B |
| 5 |
CSX Corp
CSX
|
+$1.18B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$4.2B |
| 2 |
Microsoft
MSFT
|
+$3.24B |
| 3 |
Amazon
AMZN
|
+$2.75B |
| 4 |
Netflix
NFLX
|
+$2.53B |
| 5 |
Apple
AAPL
|
+$2.48B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 35.66% |
| 2 | Financials | 11.78% |
| 3 | Healthcare | 11.44% |
| 4 | Consumer Discretionary | 10.75% |
| 5 | Communication Services | 10.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1951
Liberty Live Group Series A
LLYVA
$9.59B
| $1.32M | ﹤0.01% |
16,221
+630
| +4% | +$52.4K |
|
1952
John Wiley & Sons Class A
WLY
$2.63B
| $1.32M | ﹤0.01% |
42,965
+3,686
| +9% | +$130K |
|
1953
Scorpio Tankers
STNG
$3.81B
| $1.31M | ﹤0.01% |
25,862
+1,356
| +6% | +$77.4K |
|
1954
Asana
ASAN
$2.28B
| $1.31M | ﹤0.01% |
95,834
+4,578
| +5% | +$62.9K |
|
1955
Intuitive Machines
LUNR
$2.82B
| $1.31M | ﹤0.01% |
80,694
+20,815
| +35% | +$241K |
|
1956
Amylyx Pharmaceuticals
AMLX
$2.6B
| $1.3M | ﹤0.01% |
107,548
+7,103
| +7% | +$96.5K |
|
1957
Cadre Holdings
CDRE
$1.44B
| $1.3M | ﹤0.01% |
31,738
+1,104
| +4% | +$45.9K |
|
1958
Energizer
ENR
$1.56B
| $1.29M | ﹤0.01% |
64,905
+60
| +0.1% | +$1.31K |
|
1959
National Healthcare
NHC
$3.47B
| $1.29M | ﹤0.01% |
9,403
+580
| +7% | +$74.9K |
|
1960
Liquidia Corp
LQDA
$6.45B
| $1.28M | ﹤0.01% |
37,111
-22,902
| -38% | -$652K |
|
1961
Nelnet
NNI
$4.52B
| $1.28M | ﹤0.01% |
9,624
-1,857
| -16% | -$243K |
|
|
PMT
1962
PennyMac Mortgage Investment
PMT
$827M
| $1.27M | ﹤0.01% |
101,545
+3,547
| +4% | +$44.2K |
|
1963
Enovix
ENVX
$966M
| $1.27M | ﹤0.01% |
174,265
+25,199
| +17% | +$244K |
|
1964
Barrett Business Services
BBSI
$756M
| $1.26M | ﹤0.01% |
34,910
+6,049
| +21% | +$232K |
|
1965
Hackett Group
HCKT
$278M
| $1.26M | ﹤0.01% |
64,390
+21,786
| +51% | +$413K |
|
|
VRE
1966
DELISTED
Veris Residential
VRE
| $1.26M | ﹤0.01% |
84,902
+11,452
| +16% | +$169K |
|
1967
Navient
NAVI
$867M
| $1.26M | ﹤0.01% |
97,072
+6,275
| +7% | +$78.1K |
|
1968
AnaptysBio
ANAB
$1.66B
| $1.26M | ﹤0.01% |
26,005
-273,306
| -91% | -$10.7M |
|
1969
Trupanion
TRUP
$1.33B
| $1.26M | ﹤0.01% |
33,657
+725
| +2% | +$28.5K |
|
1970
SAP
SAP
$242B
| $1.25M | ﹤0.01% |
5,156
+1,454
| +39% | +$370K |
|
1971
Yum China
YUMC
$16.2B
| $1.25M | ﹤0.01% |
26,174
-786,556
| -97% | -$36M |
|
1972
Tandem Diabetes Care
TNDM
$1.61B
| $1.25M | ﹤0.01% |
56,809
-8,994
| -14% | -$162K |
|
1973
Herbalife
HLF
$1.23B
| $1.25M | ﹤0.01% |
96,770
-9,950
| -9% | -$105K |
|
1974
Harrow
HROW
$1.48B
| $1.25M | ﹤0.01% |
25,412
+1,161
| +5% | +$48.7K |
|
1975
Huntsman Corp
HUN
$1.78B
| $1.25M | ﹤0.01% |
124,541
-38,020
| -23% | -$348K |
|
Similar funds
T. Rowe Price Associates's Q4 2025 Portfolio in Review
As of Q4 2025, T. Rowe Price Associates held 3,154 positions worth $927B, down 0.78% from $935B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
T. Rowe Price Associates's Q4 2025 filing shows 113 new, 1,841 increased, 860 reduced and 65 closed positions. Its largest new stake was Medline Inc: 7,325,104 shares worth $308M. The largest sale was NVIDIA, an estimated $4.2B.
By sector, the portfolio is most concentrated in Technology at 36% of assets, down from 36% a quarter earlier, followed by Financials and Healthcare.
- T. Rowe Price Associates's largest Q4 2025 buy was Medline Inc: 7,325,104 shares worth $308M.
- T. Rowe Price Associates added most to Lam Research in Q4 2025, an estimated $1.66B increase.
- T. Rowe Price Associates's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $4.2B.
- T. Rowe Price Associates fully exited Akero Therapeutics in Q4 2025, selling an estimated $181M.
- T. Rowe Price Associates's ten largest holdings make up 37% of its $927B portfolio in Q4 2025.
- T. Rowe Price Associates opened 113 new positions and closed 65 in Q4 2025.
- T. Rowe Price Associates's portfolio value fell 0.78% quarter-over-quarter to $927B.
Based on T. Rowe Price Associates's 13F filing for Q4 2025, filed 17 Feb 2026.